- Home
- HOMB vs VKTX Comparison
HOMB vs VKTX Comparison
Compare HOMB & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOMB
- VKTX
- Stock Information
- Founded
- HOMB 1998
- VKTX 2012
- Country
- HOMB United States
- VKTX United States
- Employees
- HOMB N/A
- VKTX N/A
- Industry
- HOMB Major Banks
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- HOMB Finance
- VKTX Health Care
- Exchange
- HOMB Nasdaq
- VKTX Nasdaq
- Market Cap
- HOMB 5.5B
- VKTX 4.7B
- IPO Year
- HOMB 2006
- VKTX 2015
- Fundamental
- Price
- HOMB $30.41
- VKTX $32.65
- Analyst Decision
- HOMB Buy
- VKTX Strong Buy
- Analyst Count
- HOMB 4
- VKTX 12
- Target Price
- HOMB $31.25
- VKTX $106.75
- AVG Volume (30 Days)
- HOMB 1.2M
- VKTX 4.1M
- Earning Date
- HOMB 01-15-2025
- VKTX 02-05-2025
- Dividend Yield
- HOMB 2.57%
- VKTX N/A
- EPS Growth
- HOMB 3.65
- VKTX N/A
- EPS
- HOMB 2.01
- VKTX N/A
- Revenue
- HOMB $969,278,000.00
- VKTX N/A
- Revenue This Year
- HOMB N/A
- VKTX N/A
- Revenue Next Year
- HOMB $1.74
- VKTX N/A
- P/E Ratio
- HOMB $15.12
- VKTX N/A
- Revenue Growth
- HOMB N/A
- VKTX N/A
- 52 Week Low
- HOMB $22.38
- VKTX $20.75
- 52 Week High
- HOMB $32.91
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- HOMB 63.76
- VKTX 25.74
- Support Level
- HOMB $28.20
- VKTX $32.51
- Resistance Level
- HOMB $28.90
- VKTX $43.55
- Average True Range (ATR)
- HOMB 0.73
- VKTX 2.05
- MACD
- HOMB 0.27
- VKTX -0.44
- Stochastic Oscillator
- HOMB 97.43
- VKTX 1.27
About HOMB Home BancShares Inc.
Home BancShares Inc is a bank holding company that operates through its wholly owned community bank subsidiary, Centennial Bank. The bank provides a broad range of commercial and retail banking, as well as related financial services, to a diverse customer base. Its customer base includes businesses, real estate developers and investors, individuals, and municipalities. The company's loan portfolio, while diversified, is typically between half and two thirds in commercial real estate loans. The company's plan emphasizes growth, both through strategic acquisitions and organically within its existing markets. The bank also emphasizes attracting experienced bankers, credit quality, and a solid balance sheet. The bank's main source of net revenue is net interest income.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.